Journal
ACS MEDICINAL CHEMISTRY LETTERS
Volume 7, Issue 6, Pages 595-600Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acsmedchemlett.6b00044
Keywords
Sorafenib; CDK8; inhibitor; DMG-out
Categories
Ask authors/readers for more resources
Using Sorafenib as a starting point, a series of potent and selective inhibitors of CDK8 was developed. When cocrystallized with CDK8 and cyclin C, these compounds exhibit a Type-II (DMG-out) binding mode.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
